[HTML][HTML] Pemphigus vulgaris and bullous pemphigoid: update on diagnosis and treatment
V Di Lernia, DM Casanova, M Goldust… - Dermatology practical & …, 2020 - ncbi.nlm.nih.gov
Autoimmune bullous disorders are a heterogeneous spectrum of skin disorders
characterized by the production of autoantibodies against adhesion molecules of the skin …
characterized by the production of autoantibodies against adhesion molecules of the skin …
Drug-induced pemphigus: A systematic review of 170 patients
Pemphigus encompasses a rare heterogeneous group of autoimmune blistering diseases
characterized by cutaneous and/or mucosal blistering. Multiple factors, such as some …
characterized by cutaneous and/or mucosal blistering. Multiple factors, such as some …
Pathogenic and protective roles of cytokines in pemphigus: a systematic review
Pemphigus is a rare and life-threatening group of blistering autoimmune diseases that
affects the skin and mucous membranes. There are two major subtypes of pemphigus …
affects the skin and mucous membranes. There are two major subtypes of pemphigus …
Insights into the host contribution of endocrine associated immune-related adverse events to immune checkpoint inhibition therapy
A Chye, I Allen, M Barnet, DL Burnett - Frontiers in Oncology, 2022 - frontiersin.org
Blockade of immune checkpoints transformed the paradigm of systemic cancer therapy,
enabling substitution of a cytotoxic chemotherapy backbone to one of immunostimulation in …
enabling substitution of a cytotoxic chemotherapy backbone to one of immunostimulation in …
Rituximab in practice: clinical evaluation of patients with pemphigus after rituximab administration
Pemphigus Vulgaris (PV) is a rare autoimmune blistering disease, which mainly causes
mucosal and/or cutaneous lesions. In June 2018, FDA approved Rituximab (RTX)—a B‐cell …
mucosal and/or cutaneous lesions. In June 2018, FDA approved Rituximab (RTX)—a B‐cell …
Paradoxical Psoriasis in Patients Receiving Therapy with Tumor Necrosis Factor Inhibitors: Potential Pathogenic Mechanisms and the Role of Genetic Factors
D Costin, AM Burlui, A Cardoneanu… - International Journal of …, 2024 - mdpi.com
TNF inhibitors (TNFi) have revolutionized the therapeutic management of various chronic
immune-mediated inflammatory diseases. Despite their known benefits, these therapies are …
immune-mediated inflammatory diseases. Despite their known benefits, these therapies are …
[HTML][HTML] Identification of an immune-related risk signature and nomogram predicting the overall survival in patients with endometrial cancer
Y Cheng, X Li, Y Dai, Y Dong, X Yang… - Journal of Gynecologic …, 2021 - ncbi.nlm.nih.gov
Objective Aimed to construct an immune-related risk signature and nomogram predicting
endometrial cancer (EC) prognosis. Methods An immune-related risk signature in EC was …
endometrial cancer (EC) prognosis. Methods An immune-related risk signature in EC was …
Investigating expression pattern of eight immune‐related genes in pemphigus patients compared with the healthy controls and after rituximab therapy: Potential roles of CTLA4 …
Pemphigus is a rare group of autoimmune diseases, which its exact molecular pathogenesis
and therapeutic biomarkers remained unknown. In this regard the expressions of eight …
and therapeutic biomarkers remained unknown. In this regard the expressions of eight …
[HTML][HTML] HLA-Cw6 Polymorphism in Autoimmune Blistering Diseases
C Ciolfi, A Sernicola, M Alaibac - Biomolecules, 2024 - mdpi.com
Autoimmune blistering diseases of the pemphigus and pemphigoid groups are immune-
mediated disorders due to circulating pathogenetic autoantibodies. Multiple human …
mediated disorders due to circulating pathogenetic autoantibodies. Multiple human …
Impact of cytotoxic T‐lymphocyte‐associated protein 4 codon 17 variant and expression on vitiligo risk
Background Cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4) is one of the essential
brakes expressed on T cells that prevent T‐cell hyperactivation‐associated autoimmune …
brakes expressed on T cells that prevent T‐cell hyperactivation‐associated autoimmune …